Redeye leaves a comment following the phase IIa topline results of IP2018 announced by the company earlier today. We are encouraged to learn that the candidate expressed statistically significant (dose-dependent) efficacy in patients with mild to moderate psychogenic ED. Accordingly, we raise our base case valuation of Initiator Pharma.

https://www.redeye.se/research/914919/initiator-pharma-positive-phase-iia-topline-results?utm_source=finwire&utm_medium=RSS

Redeye